Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 06/12 | 06/15 | 1,654 sh | $2.23 | $3,688.42 | −0.3% |
Gregory RussottiSEE REMARKS | Century TherapeuticsIPSC | Open-market sale | 06/12 | 06/15 | 2,584 sh | $2.23 | $5,762.32 | −0.5% |
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 06/08 | 06/09 | 249 sh | $2.11 | $525.39 | −0.0% |
Gregory RussottiSEE REMARKS | Century TherapeuticsIPSC | Open-market sale | 06/08 | 06/09 | 524 sh | $2.11 | $1,105.64 | −0.1% |
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 05/04 | 05/06 | 264 sh | $2.34 | $617.76 | −0.1% |
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 03/12 | 03/16 | 7,043 sh | $2.55 | $17,959.65 | −1.4% |
Gregory RussottiSEE REMARKS | Century TherapeuticsIPSC | Open-market sale | 03/12 | 03/16 | 10,076 sh | $2.55 | $25,693.8 | −1.9% |
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 03/09 | 03/11 | 247 sh | $2.54 | $627.38 | −0.0% |
Gregory RussottiSEE REMARKS | Century TherapeuticsIPSC | Open-market sale | 03/09 | 03/11 | 479 sh | $2.54 | $1,216.66 | −0.1% |
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 02/03 | 02/05 | 323 sh | $1.82 | $587.86 | −0.1% |
Chad CowanChief Scientific Officer | Century TherapeuticsIPSC | Open-market buy | 25/12/22 | 25/12/29 | 58,060 sh | $0.85 | $49,351 | +5.9% |
Pfeiffenberger BrentPresident and CEO | Century TherapeuticsIPSC | Open-market buy | 25/12/12 | 25/12/16 | 52,000 sh | $0.58 | $30,160 | +1.6% |
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 25/12/08 | 25/12/10 | 257 sh | $0.53 | $136.21 | −0.1% |
Gregory RussottiSEE REMARKS | Century TherapeuticsIPSC | Open-market sale | 25/12/08 | 25/12/10 | 526 sh | $0.53 | $278.78 | −0.1% |
Chad CowanChief Scientific Officer | Century TherapeuticsIPSC | Open-market sale | 25/11/20 | 25/11/24 | 5,462 sh | $0.50 | $2,731 | −0.6% |
Pfeiffenberger BrentPresident and CEO | Century TherapeuticsIPSC | Open-market buy | 25/11/19 | 25/11/20 | 35,000 sh | $0.50 | $17,500 | +1.1% |
Pfeiffenberger BrentPresident and CEO | Century TherapeuticsIPSC | Open-market sale | 25/11/17 | 25/11/19 | 32,456 sh | $0.45 | $14,605.2 | −1.0% |
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 25/11/03 | 25/11/05 | 292 sh | $0.59 | $172.28 | −0.1% |
Douglas CarrSVP Finance & Operations | Century TherapeuticsIPSC | Open-market sale | 25/09/08 | 25/09/10 | 263 sh | $0.50 | $131.5 | −0.1% |
Gregory RussottiSEE REMARKS | Century TherapeuticsIPSC | Open-market sale | 25/09/08 | 25/09/10 | 539 sh | $0.50 | $269.5 | −0.1% |